TABLE 3.
Antimicrobial susceptibility testing data for the strains in this study
| Strain | KP1762a | KP1810a | KP2329a | KP2611a | KP2611Sa | E. coli J53b | Transconjugantb |
|---|---|---|---|---|---|---|---|
| ST type | ST660 | ST660 | ST23 | ST23 | ST23 | ||
| Antimicrobial resistance-related genes | blaSHV-1 | blaSHV-1, ramR (G180C) | blaSHV-11 | blaSHV-11, blaSHV-12, qnrS1 and aac(6’)-Ib | blaSHV-11, blaSHV-12, qnrS1 and aac(6’)-Ib | blaSHV-12, qnrS1 and aac(6’)-Ib | |
| Antimicrobial | MIC (mg/liter)a | ||||||
| Cefazolin | ≤4 | ≤4 | ≤4 | ≥64 | ≥64 | ≤4 | ≥64 |
| Cefuroxime | 2 | 16 | 2 | 16 | 16 | 4 | 32 |
| Cefoxitin | 2 | 32 | 3 | 3 | 3 | NT | NT |
| Ceftriaxone | ≤1 | ≤1 | ≤1 | ≥64 | 8 | 0.016 | 6 |
| Ceftazidime | ≤1 | ≤1 | ≤1 | 16 | 64 | 0.094 | 12 |
| Cefepime | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Piperacillin/tazobactam | ≤4 | 16 | ≤4 | ≤4 | 8 | ≤4 | ≤4 |
| Gentamicin | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 |
| Amikacin | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 |
| Ciprofloxacin | ≤0.25 | ≤0.25 | ≤0.25 | 1 | 1 | ≤0.25 | 1 |
| Ertapenem | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 |
| Imipenem | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 |
| Tigecycline | 0.38 | 2 | 0.75 | 0.75 | 1 | NT | NT |
| Trimethoprim-sulfamethoxazole | 0.19 | 0.5 | 0.125 | 0.125 | 0.125 | NT | NT |
a
Values were MIC-correlates determined by the Vitek2 System, except for cefoxitin, trimethoprim-sulfamethoxazole, and tigecycline, which were determined by Etest.
b
Values were MIC-correlates determined by the Vitek2 System, except for ceftriaxone and ceftazidime, which were determined by Etest. NT, not tested.